GLP-1 TV · News & media
Woman says she suffered a medical emergency after taking popular weight loss drugs
Today’s cheapest GLP-1$39/mo at Wellmedr, sale price.Compare all GLP-1 prices Price read 22 Nov 2026 from the seller’s own page, ranked by price alone. That price is a compounded drug, and compounded drugs are not FDA-approved. Not from the video’s creator.Our summary
This segment, reported by senior investigative correspondent the speaker, looks at serious side effects some patients report after taking GLP-1 drugs. The speaker says Gallup found about 15 million U.S. adults have used these injectable drugs to reduce body weight, and that many doctors see them as offering dramatic benefits.
Published by CBS Mornings on YouTube
As published by the channel. Not medical advice, and not an endorsement.
What else the video covers
The report centers on another speaker of Pennsylvania. According to the video, she weighed 242 lb at age 62 and could lose only about 20 lb through diets. Her doctor, citing her diabetes risk, prescribed Wegovy and later Ozempic, both made by Novo Nordisk. She says she felt fine and had fewer cravings. Several months later, in October 2023, her husband found her unconscious on the floor. Doctors found that parts of her large intestine had died and removed it. She then went into cardiac arrest during recovery. She now has an ostomy bag, and she says she had no warning this could happen. She is suing Novo Nordisk, and her attorney says the labels do not adequately warn about gastroparesis (stomach paralysis) and bowel obstruction.
Novo Nordisk declined an on camera interview. The video says the company points to its FDA approved labeling, calls the allegations without merit and plans to defend itself. CBS contributor another speaker says the drugs help many patients but carry risks that are not outweighed by the benefits in every situation. The speaker also cites a study that found a higher risk of bowel obstruction and stomach paralysis with certain GLP-1 drugs used for weight loss. Its co-author describes these complications as relatively rare. Whether the labels were enough is expected to be argued in court.
Our summary of what is said, in our words. Doses, results and prices are the speaker’s, not advice.
Takeaways
The main points, in the order they come up. Tap a time to play from there.
- 0:00 The speaker says Gallup found about 15 million U.S. adults have used injectable GLP-1 drugs to reduce body weight.
- 0:30 Another speaker says diets let her lose only about 20 lb from 242 lb, and her doctor prescribed Wegovy and later Ozempic.
- 1:34 In October 2023 her husband found her unconscious, and doctors removed her large intestine, after which she had a cardiac arrest.
- 2:35 Another speaker is suing Novo Nordisk, claiming its labels do not adequately warn of stomach paralysis and bowel obstruction.
- 3:05 Novo Nordisk says the known risks are in its FDA approved labeling and that the allegations are without merit.
- 3:35 Another speaker says the drugs are helpful but carry risks that are not always outweighed by the benefits.
Key moments
Tap one to play from there.
Questions this video answers
What side effects did a woman report after taking Wegovy and Ozempic?
According to the video, another speaker says she was found unconscious in October 2023 and doctors found parts of her large intestine had died. It was removed, and she now has an ostomy bag. She says she had no warning this was possible.
Why is Novo Nordisk being sued over Wegovy and Ozempic?
The video says another speaker claims the drug labels do not adequately warn patients and doctors about serious side effects such as gastroparesis and bowel obstruction. Novo Nordisk says the risks are described in its FDA approved labeling and that the allegations are without merit.
Are bowel obstruction and stomach paralysis common with GLP-1 weight loss drugs?
The video cites a study that found a higher risk of these complications with certain GLP-1 drugs compared with another weight loss drug combination. The study's co-author describes them as relatively rare. He adds that a low individual risk does not mean it cannot happen to a given patient.
Videos on the same question
The closest videos in the library by what is said in them, not by title.
Understanding risks of GLP-1 weight loss drugsThis Click On Detroit segment from Local 4 is the second of two reports by the speaker on GLP-1 agonists, sold under brand names such as Wegovy, Zepbound and Saxenda.- Already on a GLP-1? What your next month costs at every programToday’s lowest is $39/mo. Every program ranked by price alone. Compounded drugs are not FDA-approved.
FDA approves Wegovy pill, the first prescription pill for weight lossAccording to the video, the channel report, the FDA has approved the first prescription pill for weight loss that uses the same medicine as injectable GLP-1 drugs.
Wegovy & Ozempic: The Ins & Outs of Weight Loss Drugs | Mark Moyad, MD & Mark Scholz, MD | PCRIIn this short conversation, the speaker, MD and the speaker, MD discuss the GLP-1 agonist class of weight loss drugs.
A Registered Dietitian's take on Ozempic, Wegovy, Semaglutide! GLP-1The speaker, a registered dietitian who says she has worked in weight loss for two decades, gives her view on GLP-1 weight loss shots such as Ozempic, Wegovy and Mounjaro.
The Dark Truth Behind Hims & Hers’ Super Bowl AdHe says the first half of the ad criticizes America's obesity epidemic and food system, and that he initially liked it.
Read next
Our guides closest to what this video covers, with prices checked weekly.
- GLP-1 heart benefits: which drugs are proven to cut heart attack and stroke risk
Six GLP-1 brands carry an FDA-approved heart indication: Wegovy, Ozempic, Rybelsus, Mounjaro, Trulicity and Victoza. Only Wegovy has it without diabetes. In the SELECT trial of 17,604 adults with heart disease and overweight, Wegovy cut heart attack, stroke and cardiovascular death from 8.0% to 6.5% (hazard ratio 0.80). Zepbound has no heart indication yet; its outcomes trial reports in 2027. Compounded versions were never tested.
- GLP-1s before surgery: do you stop Ozempic, Wegovy or Zepbound, and for how long?
Most people can keep taking a GLP-1 before elective surgery, according to 2024 guidance from five medical societies including the American Society of Anesthesiologists, which replaced its 2023 advice to hold a weekly shot for a week. People at the highest risk (early in dose increases, on a high dose, or with nausea, vomiting or bloating) may be asked to follow a liquid diet for 24 hours, have a stomach ultrasound or wait. Every label says to tell the team you take it.
- GLP-1 patient assistance programs: what Lilly Cares and Novo's PAP actually cover
Both makers run free-drug programs for people with low income and no insurance or Medicare, but neither covers its weight-loss GLP-1. Novo Nordisk's Patient Assistance Program supplies Ozempic injections free to uninsured patients at or below 200% of the federal poverty level, and lists no Wegovy and no pills. Lilly Cares lists Trulicity as its only GLP-1: no Mounjaro, no Zepbound, no Foundayo. For weight loss, the realistic low-cost routes are the Medicare GLP-1 Bridge at $50 a month and the cash market.
Next steps
Ozempic prices
Find more like it
Side effectsThe trials
Up next
More from this collection
Watched it? See what it costs.
Every GLP-1 program we track, ranked by what actually leaves your account.




















